Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Main Article Content

A Blauvelt
RB Warren
K Reich
F Brock
F Fierens
V Ciaravino
M Lebwohl

Keywords

Psoriasis, Plaque Psoriasis, Dermatology Life Quality Index, Biologic, Tumor Necrosis Factor α, TNF-α, Certolizumab Pegol

Abstract

Abstract not available.

References

1. Gordon K. BJD 2020; doi.org/10.1111/bjd.19393

2. Blauvelt A. BJD 2020; doi.org/10.1111/bjd.19314

3. Bhosle MJ. Health Qual Life Outcomes 2006;4:35

4. Gottlieb AB. JAAD 2018;79:302–14.e6

5. Finlay AY. Clin Exp Dermatol 1994;19:210–6.